Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
Sponsor: Anders Fink-Jensen, MD, DMSci
Summary
The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-02-09
Completion Date
2024-07-21
Last Updated
2024-07-12
Healthy Volunteers
No
Conditions
Interventions
Psilocybin
A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
Locations (1)
Psychiatric Center Copenhagen
Copenhagen, Frederiksberg, Denmark